HK's Biostime to buy Australian vitamin maker Swisse for over US$1b: media
[SYDNEY] Hong Kong-listed dietary supplements company Biostime International Holdings has agreed to buy Australian vitamin maker Swisse Wellness for more than A$1.5 billion (S$1.5 billion), Australian media reported on Thursday.
The company beat Shanghai Pharmaceuticals Holding and Chinese private equity firm Hony Capital in a sale managed by Goldman Sachs Group Inc, the Australian newspaper and Fairfax Media said in reports, citing unnamed sources.
Swisse and Goldman Sachs were not immediately available for comment. Biostime issued a statement saying it had requested a trading halt for its shares, without giving an explanation.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
From legacy to launch: Francis Yeoh and Yeoh Pei Xien on family unity and YTL’s next‑gen ventures
Could Japan trigger the next global financial crisis?
Wealthy Indonesians snap up government bonds as yields near 8%: OCBC
‘You buy more picks and shovels because you keep hitting gold’: Why AI spending needs to see results
